Recent Updates
Recently added Catalysts
IRIX Positive Sentiment Score: 60/100

Iridex to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023

Thursday, February 23, 2023 2 min read
Key Takeaway: Iridex Corporation announced it will release its financial results for the fourth quarter and full year 2022 on March 9, 2023. Following the release, the management team will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET for investors to discuss the results. Iridex is known for its innovative ophthalmic laser-based medical products aimed at treating glaucoma and retinal diseases, underscoring its leadership in the medical technology industry.

Market Sentiment Analysis

POSITIVE FACTORS

  • Iridex is reporting its financial results, indicating business activity.
  • The company is preparing for a conference call to discuss results, which reflects transparency.
  • Iridex continues to innovate in ophthalmic laser-based medical products, highlighting its leadership in the field.

Full Press Release Details

MOUNTAIN VIEW, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the fourth quarter and full year 2022 after the close of trading on Thursday, March 9, 2023.
The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by accessing the live and recorded webcast on the “Event Calendar” page of the “Investors” section of the Company’s website at: www.iridex.com.
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
Investor Relations Contact:
investors@iridex.com

Frequently Asked Questions

When will Iridex announce its 2022 financial results?

Iridex will announce its 2022 financial results on March 9, 2023.

What time is the Iridex conference call scheduled?

The conference call is set for 2:00 p.m. PT / 5:00 p.m. ET.

How can investors access the Iridex conference call?

Investors can access the call via the webcast on Iridex's website.

What conditions do Iridex products treat?

Iridex products treat glaucoma and diabetic macular edema, among others.

In how many countries does Iridex distribute its products?

Iridex products are available in over 100 countries globally.

Tags: IRIX Viatris Investor Conferences Healthcare Iridex financial results ophthalmic products lasers
Last updated: Feb 23, 2023